RecruitingPhase 1Phase 2NCT05939167

Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage

A Double-blind, Randomized Placebo-controlled Clinical Trial to Investigate the Safety and Efficacy of Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage

Sponsor

Cell Energy Life Sciences Group Co. LTD

Enrollment

150 participants

Start Date

Dec 10, 2023

Study Type

INTERVENTIONAL

Conditions

AIDS

Summary

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether mesenchymal stem cell therapy (using special cells that can help repair the immune system) can improve immune function in people with advanced HIV/AIDS who still have low immune cell counts despite treatment. **You may be eligible if...** - You are between 18 and 65 years old - You have a confirmed HIV infection - Your CD4+ T cell count (immune cells) is below 500 cells/µL - You do not have any serious AIDS-defining illnesses currently - You are willing to comply with the study requirements and not join other clinical trials **You may NOT be eligible if...** - You have active serious infections or AIDS-related illnesses - You have other major medical conditions that could affect the study - You are unable to give informed consent - You are currently participating in another clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGmesenchymal stem cell

Mesenchymal stem cell dose is 0.75-1.0×10\*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).

OTHERsaline

saline is used as placebo in the placebo comparator group